25,729 articles
ZMA (supplement)
ZMA (zinc magnesium aspartate) is a Victor Conte-created SNAC trademark supplement of zinc, magnesium, and vitamin B6 taken before bed; trials show no testosterone, strength, or sleep benefit in replete users.
ZN-A-1041 (oral HER2 inhibitor)
ZN-A-1041 (ZN-1041, RO7771950, bizrolertinib) is an oral, selective HER2 tyrosine kinase inhibitor from China's Zion Pharma, designed to cross the blood-brain barrier for HER2+ breast cancer brain metastases; Roche licensed worldwide rights in 2023 for up to $680 million.
Zocilurtatug pelitecan
Zocilurtatug pelitecan (ZL-1310) is an investigational antibody-drug conjugate developed by Zai Lab that targets DLL3 and is in Phase 3 trials for relapsed small cell lung cancer.
Zolbetuximab
Zolbetuximab (Vyloy, IMAB362) is Astellas's first-in-class chimeric IgG1 antibody against claudin 18.2, approved October 2024 with chemotherapy as first-line therapy for CLDN18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinoma.
Zoledronic acid
Zoledronic acid (zoledronate; Reclast/Aclasta, Zometa) is a nitrogen-containing bisphosphonate given intravenously, 5 mg yearly for osteoporosis and Paget's disease and 4 mg monthly for skeletal complications of malignancy, reducing hip, vertebral, and nonvertebral fractures.
Zoliflodacin
Zoliflodacin (Nuzolvence, formerly AZD0914/ETX0914) is a first-in-class spiropyrimidinetrione antibiotic, a single 3 g oral dose targeting GyrB, approved by the FDA on December 12, 2025 for uncomplicated urogenital gonorrhea.
Zollinger–Ellison syndrome
Zollinger–Ellison syndrome (ZES), gastrinoma syndrome, a rare acid-hypersecretion disorder from duodenal or pancreatic gastrinomas causing ulcers, GERD, and diarrhea; 20–25% MEN1-related, diagnosed by fasting gastrin and secretin test, treated with high-dose PPIs.
Zolmitriptan
Zolmitriptan (Zomig) is a 5-HT1B/1D agonist triptan for acute migraine in adults, US-approved 1997; tablets, ODT, and nasal spray, 1.25-5 mg doses, max 10 mg/24 h.
Zolpidem
Zolpidem (Ambien, Ambien CR, Edluar, Zolpimist, Intermezzo) is an imidazopyridine nonbenzodiazepine hypnotic that selectively modulates α1-containing GABAₐ receptors; FDA-approved in 1992 for short-term insomnia treatment, Schedule IV, with a 2019 boxed warning for complex sleep behaviors.
Zombie apocalypse
Zombie apocalypse: fictional horror scenario where contagion turns humanity into infectious zombies and civilization collapses; rooted in Haitian Vodou, defined by Romero's Living Dead films, spread via Resident Evil, 28 Days Later, and The Walking Dead.
Zomepirac
Zomepirac (Zomax), a pyrrole-acetic acid NSAID related to tolmetin, was an oral nonopioid analgesic for mild to severe pain, comparable to IM morphine, withdrawn worldwide in March 1983 after fatal anaphylactoid reactions.
Zongertinib
Zongertinib (Hernexeos, BI 1810631), Boehringer Ingelheim's oral irreversible HER2-selective kinase inhibitor sparing wild-type EGFR; FDA accelerated approval 2025 and 2026 for HER2 TKD-mutant non-squamous NSCLC, ORR 76% first-line in Beamion LUNG-1.
Zonisamide
Zonisamide (Zonegran, Excegran, Trerief) is a 1,2-benzisoxazole sulfonamide antiepileptic drug blocking sodium and T-type calcium channels, approved in Japan in 1989 for epilepsy and later as adjunctive therapy for Parkinson's disease and DLB parkinsonism.
Zoonosis
Zoonosis (plural zoonoses): infectious disease naturally transmissible from vertebrate animals to humans; over 200 known types, about 60% of human pathogens, managed through the One Health approach of WHO, FAO, WOAH, and UNEP.
Zopapogene imadenovec drba
Zopapogene imadenovec-drba (PRGN-2012, PAPZIMEOS), Precigen's non-replicating adenoviral vector immunotherapy expressing HPV 6/11 fusion antigen; first FDA-approved therapy for adult recurrent respiratory papillomatosis, approved August 14, 2025.
Zopiclone
Zopiclone, a cyclopyrrolone Z-drug hypnotic (with zolpidem and zaleplon), treats short-term insomnia at 7.5 mg via GABAA receptor modulation; marketed since 1986, not FDA-approved in the US, where eszopiclone is sold instead.
Zoptarelin doxorubicin
Zoptarelin doxorubicin (AEZS-108, AN-152, Zoptrex) is a peptide-drug conjugate linking doxorubicin to a D-Lys6-LHRH agonist to target LHRH receptor-positive tumors; its Phase III endometrial cancer trial failed and development was discontinued.
Zoraya ter Beek
Zoraya ter Beek, Dutch woman (born 1995) granted euthanasia approval in May 2024 for unbearable psychiatric suffering after a 3.5-year procedure under the 2002 Dutch euthanasia law, after ten years of failed treatment including 33 ECT sessions.
Zorecimeran
Zorecimeran (CVnCoV, CV07050101) is CureVac's unmodified-mRNA, LNP-encapsulated COVID-19 vaccine encoding prefusion-stabilized SARS-CoV-2 spike; its HERALD Phase 2b/3 trial showed 48% efficacy and the EMA application was withdrawn in October 2021.
Zorifertinib hydrochloride (AZD3759)
Zorifertinib hydrochloride (AZD3759, Zerini, 盐酸佐利替尼片) is an EGFR-TKI designed to evade MDR1/BCRP efflux for brain penetration; approved in China (NMPA, November 20, 2024) as first-line therapy for EGFR-mutant NSCLC with CNS metastases after the phase 3 EVEREST trial.
Zostavax
Zostavax (zoster vaccine live) was Merck's live attenuated shingles vaccine, FDA licensed in 2006 for adults 50 and older, about 51% effective at 60+, replaced by Shingrix and discontinued in the US by November 18, 2020.
Zoster vaccine
Zoster vaccine prevents shingles from reactivated varicella-zoster virus. Shingrix (RZV, recombinant glycoprotein E plus AS01_B adjuvant, GSK) replaced the live Zostavax, giving 97% efficacy in adults 50+ and 2-dose CDC recommendations.
Zoster vaccine recombinant, adjuvanted
Zoster vaccine recombinant, adjuvanted (Shingrix, RZV) is GSK's two-dose, non-live shingles vaccine of VZV glycoprotein E plus AS01B adjuvant, FDA-approved 2017, over 90% effective against shingles and postherpetic neuralgia in adults 50 and older.
Zoster without complications
Zoster without complications (ICD-11 1E91.0) is uncomplicated shingles: reactivated VZV causing a painful single-dermatome vesicular rash that heals in 2 to 4 weeks without eye, nervous-system, disseminated, or postherpetic-neuralgia involvement.
Zosuquidar
Zosuquidar (LY335979) is a synthetic quinoline and potent, selective inhibitor of P-glycoprotein, tested against multidrug resistance in acute myeloid leukemia but never approved; it remains an experimental research tool.
Zotarolimus
Zotarolimus (ABT-578), a sirolimus analog, is the antiproliferative drug in Medtronic's Endeavor, Resolute Integrity, Resolute Onyx, and Onyx Frontier coronary stents; it inhibits mTOR via FKBP12 binding.
Zovaglutide
Zovaglutide (ZT002) is an investigational once-monthly GLP-1 receptor agonist peptide injection by Beijing QL Biopharmaceutical for obesity and type 2 diabetes, in phase 3 (HORIZON-1) in China, distinguished from weekly agents like semaglutide by monthly dosing.
ZTTK syndrome
ZTTK syndrome, also called Zhu-Tokita-Takenouchi-Kim or SON-related neurodevelopmental disorder, is a rare autosomal dominant disorder from de novo SON (21q22.11) loss-of-function variants, causing developmental delay, intellectual disability, hypotonia, seizures, facial dysmorphism, and brain, eye, skeletal, and heart-kidney anomalies.
Zuberitamab
Zuberitamab (HS006, Anruoxi) is a Chinese class 1 chimeric anti-CD20 monoclonal antibody by BioRay, approved May 2023 with CHOP for CD20-positive DLBCL; phase 3 showed non-inferior ORR and higher CR versus rituximab.
Zucapsaicin
Zucapsaicin (civamide), the synthetic cis-isomer of capsaicin, is a TRPV1 agonist analgesic; a 0.075% cream (Civanex/Zuacta) was approved in Canada in 2010 for severe knee osteoarthritis pain, and intranasal civamide was studied for migraine and cluster headache.